Med24
metabolic-therapy 1. 9. 2026 • 2 min read • Journal of veterinary internal medicine (PubMed)

Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial.

BACKGROUND: Insulin resistance, enhanced β-cell responsiveness, and lower insulin clearance contribute to hyperinsulinemia in horses with insulin dysregulation. Canagliflozin (CAN) reduces hyperinsulinemia in horses, but its effect on insulin sensitivity (IS) remains unclear. HYPOTHESIS/OBJECTIVES: Evaluate the...

MASH-riskin tunnistaminen: Tutkimus Ruotsista

The study investigated the effects of canagliflozin (CAN) on insulin-dysregulated (ID) horses. The research aimed to determine the impact of CAN on insulin sensitivity, insulin clearance, and β-cell responsiveness. Twenty privately owned ID mares participated in a randomized, double-blind, placebo-controlled trial. Horses were administered either CAN (0.4 mg/kg once daily) or a placebo for four weeks. Assessments were conducted using a euglycemic hyperinsulinemic clamp (EHC) to measure insulin sensitivity and insulin metabolic clearance rate (MCR), and a graded glucose infusion test (GGI) to evaluate β-cell responsiveness. Results indicated that insulin sensitivity (M/I) was lower with CAN compared to the placebo group (1.5 ± 0.2 mg/kg/min × 103 / [μIU/mL] versus 2.7 ± 0.2 mg/kg/min × 103 / [μIU/mL]); the least squares mean difference was -1.3 [95% CI, -1.9 to -0.6]; P < 0.001). Conversely, insulin MCR was significantly higher in the CAN group (6.5 ± 0.3 mL/kg/min versus 5.4 ± 0.3 mL/kg/min); the least squares mean difference was 1.0 [95% CI, 0.3-1.8]; P = 0.01). Furthermore, β-cell responsiveness (ΔI versus ΔG) was 43.3% lower with CAN (20.8 [95% CI, 16.9-25.5] mIU/mmol versus 36.7 [29.9-45.1] mIU/mmol); the ratio of geometric least squares means was 0.57 [95% CI, 0.42-0.76]; P < 0.001). The study concluded that β-cell responsiveness was reduced and insulin clearance was increased in the CAN-treated horses, despite apparent lower insulin sensitivity. The research suggests that higher endogenous glucose production in the CAN-treated mares may have contributed to an underestimation of insulin sensitivity.

Sponsored content

Original Scientific Source
Journal of veterinary internal medicine (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement